Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Amyloid angiopathy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cerebral amyloid angiopathy (CAA) is a condition in which proteins called amyloid build up on the walls of the arteries in the brain. CAA increases the risk for stroke caused by bleeding and dementia.
Benzothiepin derivatives, process for the preparation of the same and uses thereof
InactiveUS6355672B1Potent osteogenesis promoting effectLow toxicityBiocideOrganic chemistryDiseaseHydrogen atom
The invention provides compounds of the formula:wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect.The present invention relates to an amine compound having an excellent effect of inhibiting production and/or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and/or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.
Owner:TAKEDA PHARMA CO LTD
Prevention and treatment of cerebral amyloid angiopathy
InactiveUS20080292625A1Reduces and inhibits vascular amyloidogenic pathologyMinimizes microhemorrhageNervous disorderImmunoglobulins against animals/humansAmyloid angiopathyDisease cause
The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Rapid improvement of cognition in condition related to abeta
InactiveUS20060073149A1Rapid improvement of cognitionRapid of cognitionNervous disorderImmunoglobulins against animals/humansCognition.knowledgeS syndrome
The present invention is a method for effecting rapid improvement in cognition in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises administering anti-Aβ antibodies to the subject, especially antibodies having a high affinity for soluble forms of Aβ. X-15240
Owner:BALES KELLY +2
Prevention and treatment of cerebral amyloid angiopathy
InactiveUS20090142270A1Reduces and inhibits development of vascularMinimizes microhemorrhageNervous disorderImmunoglobulins against animals/humansAmyloid angiopathyAntibody
The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.
Owner:JANSSEN SCI IRELAND UC +1
Treatment of cerebral amyloid angiopathy
InactiveUS8003097B2Reduces and inhibits development of vascularMinimizes microhemorrhageNervous disorderImmunoglobulins against animals/humansAmyloid angiopathyAntibody
The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.
Owner:JANSSEN SCI IRELAND UC +1
New compounds 575
InactiveUS20100125087A1Shorten the progressReduce in patientBiocideNervous disorderPre-Senile DementiaAttention deficits
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Compounds and their use as BACE inhibitors
The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure:
is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
Owner:WYETH LLC
Use of edaravone in preparation of drug for preventing and treating cerebral amyloid angiopathy (CAA)
ActiveCN105616405AEliminate depositsAvoid depositionOrganic active ingredientsNervous disorderAmyloid angiopathyProtein C
The invention belongs to the field of pharmacy and relates to a use of edaravone in preparation of a drug for preventing and treating cerebral amyloid angiopathy (CAA). The edaravone can remove the amyloid protein (A beta) deposited in brain and prevent A beta deposition in brain.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Aza-peptides
Provided are peptides comprising at least one azaamino acid and having β-sheet breaking ability, useful in the treatment and prevention of diseases such as alzheimer's disease, Dementia Pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and Vascular Dementia with amyloid angiopathy.
Owner:LAB SERONO SA
Compounds and their use as BACE Inhibitors
The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Compounds 563
InactiveUS20100130495A1Reduce secretionIncrease secretion levelBiocideNervous disorderAttention deficitsSenile dementia
The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
Cyclohexane-1,2′-indene-1′,2″-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds.
Owner:ASTRAZENECA AB
Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
Cyclohexane-1,2′-naphthalene-1′,2″-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds.
Owner:ASTRAZENECA AB
Benzothiepine derivatives, their production and use
InactiveUS20020128308A1Superior in clinically useful characteristics such as stabilityPotent promoting effectBiocideOrganic chemistryDiseaseHydrogen atom
The invention provides compounds of the formula: 1 wherein the ring A is an optionally substituted benzene ring; R.sup.1 is an optionally substituted non-aromatic heterocyclic group; R.sup.2 and R.sup.3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. The present invention relates to an amine compound having an excellent effect of inhibiting production and / or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and / or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.
Owner:TAKEDA PHARMA CO LTD
Cyclohexane-1,2'-Naphthalene-1',2"-Imidazol Compounds and Their Use as Bace
Cyclohexane-1,2′-naphthalene-1′,2″-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds.
Owner:ASTRAZENECA AB
Inhibitors of beta amyloid production
Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R1-R3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and a physiologically compatible carrier. These compounds are specifically useful for inhibiting beta amyloid production, and treating Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome.
Owner:WYETH LLC
Analytical method for beta-amyloid protein pathology by using thioflavine T staining
InactiveCN103278626AClear etiologyStrong impetusFluorescence/phosphorescencePharmacological interventionsDisease patient
The invention relates to an analytical method for beta-amyloid protein pathology by using thioflavine T staining. The method comprises the following processes: A, a patient pathological specimen source, B, an experimental animal pathological specimen source, C, treatment of patient and experimental animal brain tissue specimens, D, immumohistochemical staining of specimen beta-amyloid protein 1-42, E, thioflavine T staining of the specimen, and F, optical / fluorescence microscope pathological examination. The method has the advantages of introducing and widely using the thioflavine T to mark an amyloid protein disease patient brain tissue pathological specimen and assess the pharmacological intervention effect of alzheimer disease (AD) transgenic animals; compared with the traditional silver staining method and A beta immunohistochemical method, the method provided by the invention has the characteristics of being simple and feasible, and sensitive and reliable, is beneficial for clearing the nosetiology of cerebral hemorrhage, and has great guide value on formulation of patient secondary intervening measures. The wide application of the technology has a powerful promoting effect on clinical pathological research and translational medicine research of the A beta related diseases (alzheimer disease and amyloid angiopathy).Owner:徐俊
New compounds 574
InactiveUS20100125081A1Shorten the progressReduce in patientBiocideNervous disorderPre-Senile DementiaAttention deficits
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Compounds and their use as BACE inhibitors
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
The present invention relates to the medical use of nitrites, such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, compositions, or prodrugs thereof, in the treatment of conditions that benefit from increased cerebral vascular flow. The pharmaceutical compositions used in these methods, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−).Owner:THERAVASC +1
Methods of preventing and treating cerebral amyloid angiopathy (CAA) with an edaravone medicament
InactiveUS20170312253A1Inhibit aggregationPromotes Aβ fiber disaggregationOrganic active ingredientsNervous disorderAmyloid angiopathyEndocrinology
The present invention belongs to pharmaceutical field, specifically, relates to use of Edaravone in the preparation of a medicament for preventing and treating cerebral amyloid angiopathy (CAA). By administering Edaravone, the present invention could scavenge the deposited amyloid (Aβ) in the brain and prevent the intracerebral Aβ deposition.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Owner:ASTRAZENECA AB
Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
A compound of Formula (I), or pharmaceutically acceptable salts and / or hydrates or prodrugs thereof, wherein Formula (I) has the structure:is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
Owner:WYETH LLC
Beta-Amyloid Inhibitors and Use Thereof
InactiveUS20070293422A1Suitable for treatmentImprove propertiesNervous disorderPeptide/protein ingredientsCerebral haemorrhagesAmyloid angiopathy
Peptides and derivatives or analogs thereof are provided for having β-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.
Owner:LAB SERONO SA
Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
InactiveUS20050227941A1Lower Level RequirementsImprove efficiencyBiocidePeptide/protein ingredientsAntigenAmyloid beta
The present invention describes a method of administering an Aβ-binding agent or drug which has affinity for amyloid beta (Aβ) in the periphery (blood) and reducing Aβ levels in the brain without the need for the agent or drug to enter the brain itself. The Aβ-binding agents utilized in the methods of the invention are preferably non-immunomodulating agents (e.g., antigenic peptides or antibodies) and bind to Aβ in the periphery, or blood. Such compounds do not significantly cross the blood/brain barrier, and yet they lower amyloid (Aβ) levels in the brain, thereby serving as safer, therapeutic and prophylactic treatments against diseases associated with Aβ in the brain, e.g., Alzheimer's Disease and amyloid angiopathy, as well as against other AD-related amyloidoses.
Owner:RES FOUDATION FOR MENTAL HYGIENE INC
Piezoelectric agonists to prevent or reverse abnormal amyloid deposition
PendingCN114126617AOrganic active ingredientsNervous disorderBrain pathologiesMicroglial cell activation
The present invention relates to the diagnosis, prevention, delay or reversal of pathological progression associated with abnormal amyloid deposits, such as for example Alzheimer's disease (AD). More specifically, the methods comprise administering specific molecules acting as piezoelectric agonists, such as Yoda1, Jed1, Jed2 or functional analogs thereof, capable of modulating the activation of small glial cells to an anti-inflammatory state and / or interfering with the formation of amyloid-producing peptides and / or increasing their outflow from the central nervous system. These agonists are useful in disease states associated with or at risk of developing brain amyloidosis, such as Alzheimer's disease, Parkinson's disease, stroke, head trauma, brain amyloid angiopathy, spongioencephalopathy, and pruritus. All of the diseases are evidence of abnormal pro-inflammatory microglial cell activation.
Owner:UNIVERSITY OF EASTERN FINLAND
Hucbc treatment of amyloid associated disease
ActiveUS20100150882A1Reduces cerebral Aβ depositsImproves cognitive deficitsBiocideNervous disorderHuntingtons choreaBlood plasma
Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
Owner:UNIV OF SOUTH FLORIDA
Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders
The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral administration of the liquid edaravone solution to the human patient, to provide a daily dose of 40-120 mg edaravone during an uninterrupted period of at least 10 days. Examples of oxidative stress-mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.
Owner:TREEWAY TW001 BV
Prophylactic and/or therapeutic agent for mild cognitive impairment
ActiveUS9737524B2Prevent and treat deterioration of functionImprove the quality of lifePowder deliverySenses disorderTherapeutic intentBULK ACTIVE INGREDIENT
Provided is a prophylactic and / or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and / or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and / or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and / or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and / or therapeutic drug for mild cognitive impairment can be used for the prevention and / or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down's syndrome, or macular degeneration.
Owner:FOUND FOR BIOMEDICAL RES & INNOVATION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap